Colorectal Cancer Therapeutics Market
Colorectal Cancer Therapeutics Market Size, Share & Trends Analysis Report by Types of Colorectal Cancer (Colorectal adenocarcinoma, Gastrointestinal carcinoid tumors and Others), by Therapy (Immunotherapy, Chemotherapy, Radiation therapy, and Others), and by End-Use (Hospitals and Clinics), Forecast Period (2023-2030)
Colorectal cancer therapeutics market is anticipated to grow at a CAGR of 5.8% during the forecast period (2023-2030). Several lifestyle factors contribute to the development of colorectal cancer such as a high intake of processed meats and low intake of fruits and vegetables, sedentary lifestyle, obesity, smoking, and excessive alcohol consumption. Colorectal cancer is the third most common cancer around the globe, accounting for approximately 10% of all cancer cases and is the second leading cause of cancer-related mortalities around the globe. According to the World Health Organization, in 2020, more than 1.9 million new cases of colorectal cancer and more than 930 000 deaths due to colorectal cancer were estimated to have occurred globally. The incidence rates were highest in Europe, Australia and New Zealand, and the mortality rates were highest in Eastern Europe. By 2040 the burden of colorectal cancer will increase to 3.2 million new cases per year (an increase of 63%) and 1.6 million mortalities per year (an increase of 73%). Studies have shown that screening can reduce both the incidence and mortality of colorectal cancer through early detection and removal of precancerous growths. Though, the colorectal cancer mortality has been declining over the last few years due to advanced screening and diagnostics as well as improved treatments, which is likely to drive the market growth.
Segmental Outlook
The global colorectal cancer therapeutics market is segmented on the types of colorectal cancer, therapy and end user. Based on the types of colorectal cancer, the market is sub-segmented into Colorectal adenocarcinoma, Gastrointestinal carcinoid tumors and Others. Further, others types of colorectal cancer include Primary colorectal lymphomas, and Gastrointestinal stromal tumors. Based on the therapy, the market is sub-segmented into immunotherapy, chemotherapy, radiation therapy, and others. Other therapy includes targeted therapy. Further, on the basis of end user, the market is sub-segmented into hospitals, Hospitals and Clinics. Among the end user, the hospitals sub-segment is anticipated to hold a considerable share of the market, owing to the advance facilities, easily accessible, transportation and housing assistance.
The Surgical Robot Sub-Segment is Anticipated to Hold a Considerable Share of the Global Colorectal Cancer Therapeutics Market
Among the type, the surgical robot sub-segment is expected to hold a considerable share of the global colorectal cancer therapeutics market, owing to the encouraging outcomes and offers a viable strategy for not only enhancing the quality of life but also dramatically boosting the overall survival rate of cancer patients. A study published in the National Library of Medicine in October 2022, have demonstrated that immunotherapy is a viable alternative treatment option for patients with recurrent or metastatic cancer, since the overall survival rate and progression-free survival rate were shown to be effective. Regardless of how the FDA approved the use of immunotherapy, either as an alternative or adjuvant cancer therapy, there are immunotherapies that are used as the first line of treatment against cancer. Such examples include the use of pembrolizumab as the first line of treatment in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer that has metastasized. Such positive research and results are likely to boost the growth of this segment over the forecast period.
Regional Outlook
The global colorectal cancer therapeutics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia pacific is anticipated to hold a prominent share of the market across the globe, owing to the rising treatment rates, inflated medicine prices, advanced medical technologies, the rising disposable income and improving healthcare infrastructure in emerging economies are driving the colorectal cancer therapeutics market in the Asia Pacific.
Global Colorectal Cancer Therapeutics Market Growth, by Region 2023-2030
The North America Region is Expected to Grow at a Significant CAGR in the Global Colorectal Cancer Therapeutics Market
Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. The North America market is growing owing to factors including the rising prevalence of colorectal cancer, favorable government initiatives and highly developed healthcare infrastructure. According to the American Society of Clinical Oncology (ASCO), in 2023, an estimated 153,020 adults in the US will be diagnosed with colorectal cancer. In 2023, it is estimated that 52,550 mortalities, of which 28,470 were men and 24,080 were women from this disease occur in the US. Colorectal cancer is the second leading cause of cancer death for men and women combined. It is the third leading cause of cancer death in men and the third leading cause of cancer death in women. Moreover, factors such as the emergence of more front-line therapies, upcoming launches of promising pipeline products are flued to drive market expansion in North America. In August 2023, Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. received the US FDA on LONSURF® (trifluridine/tipiracil) as a single agent or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Market Players Outlook
The major companies serving the colorectal cancer therapeutics market include Eli Lilly and Co., Genentech, Inc., Ipsen Pharma, Regeneron Pharmaceuticals, Inc., Amgen, Inc., Bayer AG, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2023, Laboratory Corporation of America Holdings, (Labcorp), a life sciences company, partnered with the Conference of National Black Churches (CNBC) to address health equity gaps in colorectal cancer screening. To raise awareness and provide expanded access to colorectal cancer screening tests, the Conference of National Black Churches distributed over 3,000 colorectal screening test kits across several urban and rural locations including Atlanta, Dallas, Memphis, Washington D.C., New Haven, Los Angeles and Richmond.
The Report Covers
- Market value data analysis of 2022 and forecast to 2030.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global colorectal cancer therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.2. Eli Lilly and Co.,
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Genentech, Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Ipsen Pharma
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Regeneron Pharmaceuticals, Inc
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. F. Hoffmann-La Roche Ltd.
3.6.1. Overview
3.6.2. Financial Analysis
3.6.3. SWOT Analysis
3.6.4. Recent Developments
3.7. Key Strategy Analysis
4. Market Segmentation
4.1. Global Colorectal Cancer Therapeutics Market by Colorectal Cancer Types
4.1.1. Hospital Robots
4.1.2. Colorectal Adenocarcinoma
4.1.3. Gastrointestinal Carcinoid Tumors
4.1.4. Others (Primary Colorectal Lymphomas, Gastrointestinal Stromal Tumors)
4.2. Global Colorectal Cancer Therapeutics Market by Therapy
4.2.1. Immunotherapy
4.2.2. Chemotherapy
4.2.3. Radiation Therapy
4.2.4. Others (Targeted Therapy)
4.3. Global Colorectal Cancer Therapeutics Market by End-User
4.3.1. Hospitals
4.3.2. Clinics
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott Laboratories
6.2. Amgen, Inc.
6.3. Bayer AG
6.4. Beckman Coulter, Inc.
6.5. Boehringer Ingelheim International GmbH
6.6. Bristol-Myers Squibb Co.
6.7. Clinical Genomics Technologies Pvt. Ltd.
6.8. EDP Biotech Corp.
6.9. Epigenomics AG
6.10. Exact Sciences Corp.
6.11. Genomictree Co., Ltd.
6.12. IMV Inc.
6.13. IngenOx Therapeutics Ltd.
6.14. ISA Pharmaceuticals B.V.
6.15. Leap Therapeutics, Inc.
6.16. Merck & co., Inc.
6.17. Metabiomics Corp.
6.18. Novartis Pharma AG
6.19. Pfizer Inc.
6.20. Quest Diagnostics Inc.
6.21. Randox Laboratories Ltd.
6.22. Sanofi Winthrop Industrie
6.23. Siemens Healthcare Pvt. Ltd.
6.24. Sumitomo Pharma Co., Ltd.
6.25. Taiho Oncology, Inc.
6.26. Teva Pharmaceutical Industries Ltd.
6.27. VolitionRX Ltd.
6.28. Zentalis Pharmaceuticals, Inc.
1. GLOBAL COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COLORECTAL CANCER TYPES, 2022-2030 ($ MILLION)
2. GLOBAL COLORECTAL ADENOCARCINOMA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
3. GLOBAL GASTROINTESTINAL CARCINOID TUMORS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
4. GLOBAL OTHER TYPES OF COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
5. GLOBAL COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2022-2030 ($ MILLION)
6. GLOBAL IMMUNOTHERAPY FOR COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
7. GLOBAL CHEMOTHERAPY FOR COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
8. GLOBAL RADIATION THERAPY FOR COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
9. GLOBAL OTHERS THERAPIES FOR COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
10. GLOBAL COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
11. GLOBAL COLORECTAL CANCER THERAPEUTICS FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
12. GLOBAL COLORECTAL CANCER THERAPEUTICS FOR CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
13. GLOBAL COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
14. NORTH AMERICAN COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
15. NORTH AMERICAN COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPES OF COLORECTAL CANCER, 2022-2030 ($ MILLION)
16. NORTH AMERICAN COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2022-2030 ($ MILLION)
17. NORTH AMERICAN COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
18. EUROPEAN COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
19. EUROPEAN COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPES OF COLORECTAL CANCER, 2022-2030 ($ MILLION)
20. EUROPEAN COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2022-2030 ($ MILLION)
21. EUROPEAN COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
22. ASIA-PACIFIC COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
23. ASIA-PACIFIC COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPES OF COLORECTAL CANCER, 2022-2030 ($ MILLION)
24. ASIA-PACIFIC COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2022-2030 ($ MILLION)
25. ASIA-PACIFIC COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
26. REST OF THE WORLD COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPES OF COLORECTAL CANCER, 2022-2030 ($ MILLION)
27. REST OF THE WORLD COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2022-2030 ($ MILLION)
28. REST OF THE WORLD COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
1. GLOBAL COLORECTAL CANCER THERAPEUTICS MARKET SHARE BY TYPES OF COLORECTAL CANCER, 2022 VS 2030 (%)
2. GLOBAL COLORECTAL ADENOCARCINOMA THERAPEUTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
3. GLOBAL GASTROINTESTINAL CARCINOID TUMORS THERAPEUTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
4. GLOBAL OTHER TYPES OF COLORECTAL CANCER THERAPEUTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
5. GLOBAL COLORECTAL CANCER THERAPEUTICS MARKET SHARE BY THERAPY, 2022 VS 2030 (%)
6. GLOBAL IMMUNOTHERAPY FOR COLORECTAL CANCER MARKET SHARE BY REGION, 2022 VS 2030 (%)
7. GLOBAL CHEMOTHERAPY FOR COLORECTAL CANCER MARKET SHARE BY REGION, 2022 VS 2030 (%)
8. GLOBAL RADIATION THERAPY FOR COLORECTAL CANCER MARKET SHARE BY REGION, 2022 VS 2030 (%)
9. GLOBAL OTHERS THERAPY FOR COLORECTAL CANCER MARKET SHARE BY REGION, 2022 VS 2030 (%)
10. GLOBAL COLORECTAL CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022 VS 2030 (%)
11. GLOBAL COLORECTAL CANCER THERAPEUTICS FOR HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
12. GLOBAL COLORECTAL CANCER THERAPEUTICS FOR CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
13. GLOBAL COLORECTAL CANCER THERAPEUTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
14. US COLORECTAL CANCER THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
15. CANADA COLORECTAL CANCER THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
16. UK COLORECTAL CANCER THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
17. FRANCE COLORECTAL CANCER THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
18. GERMANY COLORECTAL CANCER THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
19. ITALY COLORECTAL CANCER THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
20. SPAIN COLORECTAL CANCER THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
21. REST OF EUROPE COLORECTAL CANCER THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
22. INDIA COLORECTAL CANCER THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
23. CHINA COLORECTAL CANCER THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
24. JAPAN COLORECTAL CANCER THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
25. SOUTH KOREA COLORECTAL CANCER THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
26. REST OF ASIA-PACIFIC COLORECTAL CANCER THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
27. REST OF THE WORLD COLORECTAL CANCER THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
